
Founder & Managing Director at Bridge Informatics. I'm passionate about #informatics, #datainfrastructure, #biostatistics, #drugdiscovery, #bioinformatics.
Boston, MA
Joined March 2012
- Tweets1.6K
- Following1.7K
- Followers1.2K
- Likes2.5K
Dan Ryder retweeted
ICYMI: We delved into groundbreaking research that harnessed #AI deep learning models to decipher the intricate “enhancer codes” hidden within our DNA. These enhancer codes play a crucial role in controlling cell identity. Read more: bridgeinformatics.com/ai-dee…
Dan Ryder retweeted
ICYMI: A new computational tool, MERCI, has the potential to reshape oncological research and prognostic assessments: bridgeinformatics.com/target… #MitochondrialTransfer #CancerResearch #MERCIAlgorithm #LifeSciences
This turned out to be a really fun conference!
We presented a poster at #BioITExpo last week on a single-cell RNA sequencing (scRNA-seq) analysis we performed. Click here to view the poster and see how we dissected transcriptional profiles of complex biological systems at a single cell level: bridgeinformatics.com/poster…
1
85
Dan Ryder retweeted
We presented a poster at #BioITExpo last week on a single-cell RNA sequencing (scRNA-seq) analysis we performed. Click here to view the poster and see how we dissected transcriptional profiles of complex biological systems at a single cell level: bridgeinformatics.com/poster…
Dan Ryder retweeted
We’re here at #BioIT2024 in Boston! Come visit us at poster # 8 where we’re presenting on how to move from raw sequencing data to fully annotated cell clusters using #singlecell #RNAseq #singlecell
Dan Ryder retweeted
Today we should celebrate the perseverance of $VRTX in translating the incredible human genetics of Nav 1.8 for pain into a drug with Phaase 3 data ready for approval. The commercial market can debate the differentiation and merits vs existing generics, but it should be a huge celebration for novel science and the value of the genetic validation of targets in drug discovery - which instills the confidence in expensive, long-term, multi-candidate R&D programs against these genetic targets.
Dan Ryder retweeted
Hospital in Spain offers home-brewed CAR-T cell therapy at 1/3 of commercial cost.
Hospitals can’t manufacture most medicines. But for CAR-T, patients’ own cells are removed + reprogrammed + returned to kill cancer.
“The process is the product”
🇪🇸 🧫
statnews.com/2023/12/19/car-…
Dan Ryder retweeted
ICYMI: Can bacteria be living biosensors? Read about the remarkable approach of engineering bacteria to detect cancerous DNA in models of colorectal cancer in our blog: bridgeinformatics.com/harnes…
Dan Ryder retweeted
As researchers continue to uncover connections between mind & body, they're better equipped to develop more effective treatment strategies. Today’s blog explores how stress management could enhance treatment success for IBD patients: bridgeinformatics.com/blog
Dan Ryder retweeted
ICYMI: Have you read about the newest applications for uncovering the architecture of gene regulatory networks? Last month's blog explains what they are and how to use them: lnkd.in/g6dyumXM
#bioinformatics #bridgeinformatics
Dan Ryder retweeted
AAV-Perturb-seq allows researchers to peer into the intricate world of geneotype to phenotype correlations with unprecedented precision. Learn more in today’s blog: bridgeinformatics.com/an-in-…
Dan Ryder retweeted
ICYMI: How can CAR-T therapy be applied to new cancer types? In a recent paper, researchers analyzed RNA-Seq data for novel, safe targets to treat acute myeloid leukemia (AML). Read more on BI's blog: ow.ly/E6LX50PIeTE
This conference is very engaging, such a pleasant surprise. Most interesting topics so far: hype around AI, what LPs think about funding VC in this environment, what your posture over Zoom says about you, and DEI in startup environment.
#ack2023
Excellent (and engaging) conversations going on so far at the Nantucket Conference. Thanks @ScottKirsner et al for making it happen!
#ack2023
1
77
Dan Ryder retweeted
We are proud to showcase our progress at SITC’s annual meeting this November. Poster #1001 “CAT-248 demonstrates in vivo expansion, tumor infiltration, and durable regression of multiple CD70-expressing xenograft tumors” will be presented at #SITC23 on Friday Nov 3rd!
Dan Ryder retweeted
Really excited about my upcoming course on #python for #datascience automation. Many companies are shifting to python for process automation. You’ll learn how in my course. Learn more. buff.ly/3439K41
PS - It’s great for #rstats users that want to learn Python.
Dan Ryder retweeted
Freenome, high-profile liquid biopsy company, quietly replaces its CEO
statnews.com/2021/05/21/free…
Dan Ryder retweeted
The eternal biotech startup conundrum: should I invest in building platform 🏗, products 💊 or partnerships 🤝?
Conventional wisdom: choose 2 (that aren’t platform).
We finally have the rise of true bio platform co’s; #BioTwitter: examples of early co’s that balance all 3?





















